{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:02:09Z","timestamp":1775304129520,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011594","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000}}],"reference-count":144,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011594.pub2","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T04:22:41Z","timestamp":1544502161000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD)"],"prefix":"10.1002","volume":"2018","author":[{"given":"Han","family":"Ni","sequence":"first","affiliation":[{"name":"SEGi University; Faculty of Medicine; Hospital Sibu, Jalan Ulu Oya Sibu Sarawak Malaysia 96000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soe","family":"Moe","sequence":"additional","affiliation":[{"name":"Melaka Manipal Medical College; Community Medicine; Melaka Melaka Malaysia 75150"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zay","family":"Soe","sequence":"additional","affiliation":[{"name":"UCSI University; Internal Medicine; Terengganu Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay Thi","family":"Myint","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, SEGi University; Ophthalmology; Sibu Sarawak Malaysia 96000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K Neelakantan","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"P K Das Institute of Medical Sciences; Department of Internal Medicine; Vaniamkulam, Ottapalam-679522 Kerala India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"key":"10.1002\/14651858.CD011594.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12931-015-0250-2","article-title":"Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)","volume":"16","author":"Bateman","year":"2015","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0002|cit2","first-page":"PA1499","article-title":"Efficacy and safety of aclidinium\/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity","volume":"46","author":"D'Urzo","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0003|cit3","unstructured":"EUCTR2011-001524-38-GB Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-001524-38-GB"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0004|cit4","first-page":"A3764","article-title":"The effect of aclidinium\/formoterol fixed-dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM\/COPD study","volume":"189","author":"Jones","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2147\/COPD.S114566","article-title":"The efficacy of aclidinium\/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis","volume":"11","author":"Miravitlles","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"OA1968","DOI":"10.1183\/13993003.congress-2015.OA1968","article-title":"Morning and night time symptoms in COPD and efficacy of aclidinium\/formoterol in symptomatic vs asymptomatic patients","volume":"46","author":"Miravitlles","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0007|cit7","unstructured":"NCT01462942 Long\u00adterm efficacy and safety of aclidinium\/formoterol fixed\u00addose combination clinicaltrials.gov\/ct2\/show\/NCT01462942"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011594.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"375A","DOI":"10.1378\/chest.1796046","article-title":"Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed-dose combination in patients with COPD: the ACLIFORM study","volume":"145","author":"Singh","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0009|cit9","first-page":"A5987","article-title":"Aclidinium\/formoterol fixed-dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM\/COPD study","volume":"189","author":"Singh","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2466-14-178","article-title":"Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study","volume":"14","author":"Singh","year":"2014","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Aymerich JG Watz H Beeh KM Paggiaro P Moya M Notari M Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE European Respiratory Journal 2017 PA4964","DOI":"10.1183\/1393003.congress-2017.PA4964"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0012|cit12","unstructured":"EUCTR2014-005318-50-HU A multiple dose, randomised, double-blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide\/formoterol fumarate fixed-dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-005318-50-HU"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0013|cit13","unstructured":"NCT02424344 Effect of aclidinium\/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients clinicaltrials.gov\/ct2\/show\/NCT02424344"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0014|cit14","first-page":"A3593","article-title":"Effect of aclidinium\/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study","volume":"195","author":"Watz","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Watz H Troosters T Beeh KM Garcia Aymerich J Paggiaro P Molins E ACTIVATE: effect of aclidinium\/formoterol on physical activity in patients with COPD European Respiratory Journal 2017 PA687","DOI":"10.1183\/1393003.congress-2017.PA687"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2147\/COPD.S143488","article-title":"ACTIVATE: the effect of aclidinium\/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD","volume":"12","author":"Watz","year":"2017","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12931-015-0250-2","article-title":"Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)","volume":"16","author":"Bateman","year":"2015","journal-title":"Respiratory Research"},{"issue":"4","key":"10.1002\/14651858.CD011594.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1025A","DOI":"10.1378\/chest.1780390","article-title":"Efficacy and safety of fixed-dose combination aclidinium bromide\/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial","volume":"144","author":"D'Urzo","year":"2013","journal-title":"Chest"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD011594.pub2-BIB0019|cit19","first-page":"P286","article-title":"One-year efficacy of aclidinium\/formoterol fixed-dose combination in COPD patients: the AUGMENT COPD study","volume":"44","author":"D'Urzo","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011594.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"426A","DOI":"10.1378\/chest.1821799","article-title":"The AUGMENT COPD trial: efficacy and safety of a fixed-dose combination of aclidinium bromide and formoterol fumarate in COPD patients","volume":"145","author":"D'Urzo","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0021|cit21","first-page":"A6006","article-title":"Efficacy of fixed-dose combination aclidinium bromide\/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD","volume":"189","author":"D'Urzo","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0022|cit22","first-page":"A3776","article-title":"Twice-daily aclidinium bromide\/formoterol fumarate fixed-dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD","volume":"189","author":"D'Urzo","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-014-0123-0","article-title":"Efficacy and safety of fixed-dose combinations of aclidinium bromide\/formoterol fumarate: the 24-week, randomised, placebo-controlled AUGMENT COPD study","volume":"15","author":"D'Urzo","year":"2014","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"PA1499","DOI":"10.1183\/13993003.congress-2015.PA1499","article-title":"Efficacy and safety of aclidinium\/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity","volume":"46","author":"D'Urzo","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2147\/COPD.S114566","article-title":"The efficacy of aclidinium\/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis","volume":"11","author":"Miravitlles","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"OA1968","DOI":"10.1183\/13993003.congress-2015.OA1968","article-title":"Morning and night time symptoms in COPD and efficacy of aclidinium\/formoterol in symptomatic vs asymptomatic patients","volume":"46","author":"Miravitlles","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0027|cit27","unstructured":"NCT01437397 Efficacy, safety and tolerability of aclidinium bromide\/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC) clinicaltrials.gov\/ct2\/show\/NCT01437397"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0028|cit28","unstructured":"NCT01437397 Efficacy, safety and tolerability of aclidinium bromide\/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC) clinicaltrials.gov\/ct2\/show\/NCT01437397"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0029|cit29","first-page":"A6007","article-title":"Fixed-dose combination of aclidinium bromide\/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial","volume":"189","author":"Rennard","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2017.02.008","article-title":"A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium\/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease","volume":"125","author":"D'Urzo","year":"2017","journal-title":"Respiratory Medicine"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD011594.pub2-BIB0031|cit31","first-page":"P2413","article-title":"Efficacy and tolerability of aclidinium bromide\/formoterol fumarate fixed-dose combination in patients with COPD: a one-year study","volume":"44","author":"Make","year":"2014","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0032|cit32","unstructured":"NCT01572792 Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide\/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT01572792"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0033|cit33","unstructured":"NCT01572792 Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide\/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT01572792"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0034|cit34","first-page":"A6008","article-title":"Long-term safety of fixed-dose combination aclidinium bromide\/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial","volume":"189","author":"Rennard","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.rmed.2016.05.007","article-title":"Long-term safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: results of a randomised one-year trial inpatients with COPD","volume":"116","author":"Donohue","year":"2016","journal-title":"Respiratory Medicine"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011594.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"386A","DOI":"10.1378\/chest.1825327","article-title":"Long-term safety of a fixed-dose combination of aclidinium bromide\/formoterol fumarate in patients with stable moderate to severe COPD","volume":"145","author":"Make","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0037|cit37","first-page":"A6010","article-title":"Lung function and safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: results of a one-year trial in patients with COPD","volume":"189","author":"Make","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0038|cit38","unstructured":"NCT01437540 Safety and tolerability of aclidinium bromide\/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC) clinicaltrials.gov\/ct2\/show\/NCT01437540"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0039|cit39","unstructured":"NCT00706914 Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT00706914"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0040|cit40","unstructured":"EUCTR2007-004435-30-CZ A randomised, four-week, placebo-controlled, double-blind, six arm parallel group, dose-finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 & 18 \u00b5g) combined with the inhaled anticholinergic aclidinium bromide 200 \u00b5g, aclidinium bromide 200 \u00b5g monotherapy and formoterol 12 \u00b5g monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-004435-30-CZ"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0041|cit41","unstructured":"NCT00626522 Aclidinium\/formoterol fixed combination dose finding study clinicaltrials.gov\/ct2\/show\/NCT00626522"},{"issue":"Suppl IV","key":"10.1002\/14651858.CD011594.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1136\/thx.2010.150987.38","article-title":"Efficacy and safety of once-daily aclidinium bromide 200 \u03bcg in combination with formoterol in patients with COPD","volume":"65","author":"Sliwinski","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0043|cit43","unstructured":"NCT01078623 Efficacy and safety of two fixed dose combinations of aclidinium bromide with formoterol fumarate (ALIGHT-COPD) clinicaltrials.gov\/ct2\/show\/NCT01078623"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0044|cit44","unstructured":"NCT03181880 To evaluate effectiveness of aclidinium bromide\/formoterol fumarate dihydrate in chronic obstructive pulmonary disease clinicaltrials.gov\/show\/NCT03181880"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0045|cit45","unstructured":"EUCTR2007-003648-31 A phase IIa, randomised, multicentre, evaluator-blinded, 4-way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formoterol 12 \u00b5g qd delivered by two different dry powder inhalers (Aerolizer\u00ae and Almirall Inhaler), of the fixed dose combination formoterol 12 \u00b5g + aclidinium bromide 200 \u00b5g qd delivered by Almirall inhaler, and of formoterol 12 \u00b5g bid delivered by Aerolizer\u00ae, in moderate to severe chronic obstructive pulmonary disease patients www.clinicaltrialsregister.eu\/ctr-search\/search?query=2007-003648-31"},{"issue":"4, Supp 2","key":"10.1002\/14651858.CD011594.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"45A","DOI":"10.1378\/chest.1991652","article-title":"Pharmacokinetics, safety, and tolerability of aclidinium\/formoterol fixed dose combination via Pressair\/Genuair vs formoterol via Foradil aerolizer in patients with moderate to severe COPD","volume":"146","author":"Fogarty","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0047|cit47","unstructured":"NCT01551888 Pharmacokinetic, safety and tolerability study of aclidinium\/formoterol fixed dose combination and formoterol in patients with moderate to severe chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT01551888"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0048|cit48","unstructured":"ISRCTN11017699 Histological, cellular and molecular investigation of steroid responsiveness in chronic obstructive pulmonary disease - the HISTORIC study apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN11017699"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0049|cit49","unstructured":"EUCTR2009-015901-38 Efficacy, safety and tolerability of two fixed-dose combinations of aclidinium bromide with two doses of formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo all administered twice daily in stable, moderate to severe chronic obstructive pulmonary disease patients apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-015901-38-DE"},{"issue":"4","key":"10.1002\/14651858.CD011594.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"747A","DOI":"10.1378\/chest.1703061","article-title":"Dose-ranging study of two fixed-dose combinations of twice-daily aclidinium bromide plus formoterol in patients with moderate to severe COPD","volume":"144","author":"Kerwin","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0051|cit51","unstructured":"NCT01049360 Efficacy and safety study of two fixed\u00addose combinations of aclidinium bromide with formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo (LAC\u00adMD\u00ad27) clinicaltrials.gov\/ct2\/show\/NCT01049360"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0052|cit52","unstructured":"EUCTR2016-000734-21-GB Investigating the mechanism of inhaled corticosteroids associated pneumonia by longitudinal characterisation of the airway microbiome in patients with severe COPD - microbiome use to stratify use of inhaled corticosteroids: MUSIC apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-000734-21-GB"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0053|cit53","unstructured":"NCT02972476 Microbiome use to stratify use of inhaled corticosteroids: MUSIC trial clinicaltrials.gov\/show\/NCT02972476"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0054|cit54","unstructured":"NCT02429765 Effect of aclidinium\/formoterol on night time lung function and morning symptoms in chronic obstructive pulmonary disease clinicaltrials.gov\/show\/NCT02429765"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0055|cit55","unstructured":"NCT03104634 The effects of inhaled aclidinium bromide\/formoterol fumarate on inspiratory pleural pressures in smokers: a randomised, double-blind, placebo-controlled, cross-over trial clinicaltrials.gov\/ct2\/show\/NCT03104634"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0056|cit56","unstructured":"EUCTR2016-003989-12-NL The effect of twice daily aclidinium bromide\/formoterol fumarate 340\/12 mcg vs once daily tiotropium 'Respimat' 5 mcg on static and dynamic hyperinflation in patients with COPD during 24 hours (BOTH) apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-003989-12-NL"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0057|cit57","unstructured":"NCT03275116 The effect of twice daily aclidinium bromide\/formoterol fumarate 340\/12 mcg vs once daily tiotropium 'Respimat' 5 mcg on static and dynamic hyperinflation in patients with COPD during 24 hours (BOTH) clinicaltrials.gov\/ct2\/show\/NCT03275116"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0058|cit58","unstructured":"NCT03276078 A phase IIa, open-label, repeat-dose clinical trial to evaluate the pharmacokinetics, safety and tolerability of aclidinium bromide\/formoterol fumarate fixed dose combination administered twice-daily by inhalation in Chinese patients with moderate to severe chronic obstructive pulmonary disease clinicaltrials.gov\/ct2\/show\/NCT03276078"},{"issue":"8","key":"10.1002\/14651858.CD011594.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/17425247.2013.808186","article-title":"Preference, satisfaction and errors with two dry powder inhalers in patients with COPD","volume":"10","author":"Palen","year":"2013","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"PA989","DOI":"10.1183\/13993003.congress-2015.PA989","article-title":"Overall and cardiovascular safety of aclidinium\/formoterol fixed-dose combination versus salmeterol\/fluticasone in patients with COPD","volume":"46","author":"Beier","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0061|cit61","unstructured":"EUCTR2013-000116-14-HU A randomised, double-blind, double-dummy, active-controlled study evaluating the efficacy, safety and tolerability of twice-daily aclidinium bromide \/formoterol fumarate compared with twice-daily salmeterol\/fluticasone propionate for 24-weeks treatment in symptomatic patients with chronic obstructive pulmonary disease (COPD) apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-000116-14-HU"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0062|cit62","unstructured":"NCT01908140 Study of aclidinium bromide\/formoterol fumarate compared with salmeterol\/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT01908140"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD011594.pub2-BIB0063|cit63","first-page":"PA2960","article-title":"Efficacy of aclidinium\/formoterol fixed-dose combination versus salmeterol\/fluticasone in COPD","volume":"46","author":"Vogelmeier","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0064|cit64","first-page":"A3974","article-title":"The efficacy and safety of aclidinium\/formoterol fixed-dose combination compared with salmeterol\/fluticasone in patients with COPD: results from a phase III study","volume":"191","author":"Vogelmeier","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011594.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1183\/13993003.00216-2016","article-title":"Efficacy and safety of aclidinium\/formoterol versus salmeterol\/fluticasone: a phase 3 COPD study","volume":"48","author":"Vogelmeier","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0066|cit66","unstructured":"EUCTR2015-005444-33-GB A 24 week treatment, multicentre, randomised, double blinded, double dummy, parallel-group, clinical trial evaluating the efficacy and safety of aclidinium bromide 400 \u00b5g\/formoterol fumarate 12 \u00b5g fixed-dose combination BID compared with each monotherapy (aclidinium bromide 400 \u00b5g BID and formoterol fumarate 12 \u00b5g BID) and tiotropium 18 \u00b5g QD when administered to patients with stable chronic obstructive pulmonary disease - AMPLIFY apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-005444-33-GB"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0067|cit67","unstructured":"NCT02796677 AMPLIFY - D6571C00001 Duaklir USA phase III study clinicaltrials.gov\/show\/NCT02796677 2016"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0068|cit68","unstructured":"NCT03022097 Study to patients with stable COPD to assess the efficacy and safety of aclidinium bromide\/formoterol fumarate (DUAKLIR) clinicaltrials.gov\/show\/NCT03022097"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0069|cit69","unstructured":"Almirall Clinical trials registry and results www.almirall.com\/en\/about-almirall\/research-and-development\/clinical-trials"},{"issue":"3","key":"10.1002\/14651858.CD011594.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006101","article-title":"Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease","author":"Appleton","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0071|cit71","unstructured":"AstraZeneca AstraZeneca Clinical Trials astrazenecagrouptrials.pharmacm.com\/ST\/Submission\/Search"},{"issue":"3","key":"10.1002\/14651858.CD011594.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","article-title":"Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society","volume":"155","author":"Qaseem","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011594.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM200007273430407","article-title":"Chronic obstructive pulmonary disease","volume":"343","author":"Barnes","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12931-015-0250-2","article-title":"Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)","volume":"16","author":"Bateman","year":"2015","journal-title":"Respiratory Research"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1378\/chest.12-0930","article-title":"The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically","volume":"143","author":"Bauer","year":"2013","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD011594.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.pupt.2009.05.001","article-title":"Bronchodilator effects of indacaterol and formoterol in patients with COPD","volume":"22","author":"Beier","year":"2009","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0077|cit77","first-page":"237","article-title":"Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol","volume":"6","author":"Beier","year":"2011","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rmed.2007.09.011","article-title":"Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease","volume":"102","author":"Berger","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011594.pub2-BIB0079|cit79","first-page":"1078","article-title":"Indoor air pollution in developing countries: a major environmental and public health challenge","volume":"78","author":"Bruce","year":"2000","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/16000617.0043-2016","article-title":"LABA\/LAMA combination in COPD: a meta-analysis on the duration of treatment","volume":"26","author":"Calzetta","year":"2017","journal-title":"European Respiratory Review"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2017.06.020","article-title":"Impact of LABA\/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysis","volume":"129","author":"Calzetta","year":"2017","journal-title":"Respiratory Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011594.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40261-018-0646-0","article-title":"Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment","volume":"38","author":"Capel","year":"2018","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"10.1002\/14651858.CD011594.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","article-title":"The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD011594.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1517\/14656566.2013.776539","article-title":"Aclidinium bromide\/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease","volume":"14","author":"Cazzola","year":"2013","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1183\/09031936.06.00024505","article-title":"Epidemiology and costs of chronic obstructive pulmonary disease","volume":"27","author":"Chapman","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"9","key":"10.1002\/14651858.CD011594.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009157.pub2","article-title":"Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease","author":"Chong","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"23","key":"10.1002\/14651858.CD011594.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1056\/NEJMra0804752","article-title":"Immunologic aspects of chronic obstructive pulmonary disease","volume":"360","author":"Cosio","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Criner GJ Bourbeau J Diekemper RL Ouellette DR Goodridge D Hernandez P Prevention of acute exacerbations of chronic obstructive pulmonary disease: American College of Chest Physicians and Canadian Thoracic Society Guideline Chest 2015 894 942","DOI":"10.1378\/chest.14-1676"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41533-016-0009-3","article-title":"Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD","volume":"27","author":"D'Urzo","year":"2017","journal-title":"Primary Care Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"de Miguel-Diez J Jimenez-Garcia R Considerations for new dual-acting bronchodilator treatments for chronic obstructive pulmonary disease Expert Opinion on Investigational Drugs 2014 453 6","DOI":"10.1517\/13543784.2014.876409"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2017.03.001","article-title":"Symptom variability and control in COPD: advantages of dual bronchodilation therapy","volume":"125","author":"Marco","year":"2017","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0092|cit92","unstructured":"FDA United States Food and Drug Administration www.fda.gov\/"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0093|cit93","unstructured":"Food Drug Administration FDA approved drug products: Arcapta neohaler (indacaterol inhalation powder) www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022383s002lbl.pdf"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0094|cit94","unstructured":"Food Drug Administration Drug approval package; Tudorza Pressair (aclidinium bromide) inhalation powder www.accessdata.fda.gov\/drugsatfda_docs\/label\/...\/202450s000lbl.pdf"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0095|cit95","unstructured":"Food Drug Administration FDA approved drug products: Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204275s000lbl.pdf"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0096|cit96","unstructured":"Food Drug Administration Drug approval package: Ellipta (umeclidinium \/vilanterol) powder for inhalation www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203975Orig1s000TOC.cfm"},{"issue":"6","key":"10.1002\/14651858.CD011594.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1378\/chest.123.6.1817","article-title":"Cardiovascular safety of salmeterol in COPD","volume":"123","author":"Ferguson","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0098|cit98","unstructured":"Forest Pharmaceuticals Inc Research and Development www.frx.com\/Research"},{"issue":"13","key":"10.1002\/14651858.CD011594.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","article-title":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","volume":"173","author":"Gershon","year":"2013","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0100|cit100","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018 Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report) www.goldcopd.org\/"},{"issue":"6","key":"10.1002\/14651858.CD011594.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1378\/chest.13-1349","article-title":"Passive smoking exposure is associated with increased risk of COPD in never smokers","volume":"145","author":"Hagstad","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD011594.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1378\/chest.12-2438","article-title":"Evaluating the safety of COPD medications: an evidence-based review","volume":"144","author":"Hanania","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0103|cit103","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1164\/ajrccm.158.supplement_2.13tac110","article-title":"The beta-adrenoceptor","volume":"158","author":"Johnson","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0105|cit105","unstructured":"Karakiulakis G Roth M Muscarinic receptors and their antagonists in COPD: anti-inflammatory and anti-remodeling effects www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3512336\/"},{"issue":"4","key":"10.1002\/14651858.CD011594.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008989.pub2","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","author":"Karner","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD011594.pub2-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010177.pub2","article-title":"Long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Kew","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"17","key":"10.1002\/14651858.CD011594.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1080\/14656566.2017.1403583","article-title":"A review of current and developing fixed-dose LABA\/LAMA combinations for treating COPD","volume":"18","author":"Lal","year":"2017","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD011594.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/1753465812463626","article-title":"The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease","volume":"6","author":"Maltais","year":"2012","journal-title":"Therapeutic Advances in Respiratory Disease"},{"issue":"9589","key":"10.1002\/14651858.CD011594.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(07)61380-4","article-title":"Global burden of COPD: risk factors, prevalence, and future trends","volume":"370","author":"Mannino","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011594.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1378\/chest.12-1801","article-title":"Preventing acute exacerbations and hospital admissions in COPD","volume":"143","author":"Marchetti","year":"2013","journal-title":"Chest"},{"issue":"7","key":"10.1002\/14651858.CD011594.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1517\/14656566.2014.899581","article-title":"Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease","volume":"15","author":"Matera","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD011594.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12325-016-0299-4","article-title":"Efficacy and safety of aclidinium\/formoterol versus tiotropium in COPD: results of an indirect treatment comparison","volume":"33","author":"Medic","year":"2016","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2147\/COPD.S114566","article-title":"The efficacy of aclidinium\/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis","volume":"11","author":"Miravitlles","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1476-5381.2010.01190.x","article-title":"Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD","volume":"163","author":"Moulton","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0116|cit116","doi-asserted-by":"crossref","unstructured":"Mullerova H Maselli DJ Locantore N Vestbo J Hurst JR Wedzicha J Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort Chest 2015 999 1007","DOI":"10.1378\/chest.14-0655"},{"issue":"9","key":"10.1002\/14651858.CD011594.pub2-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006829.pub2","article-title":"Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Nannini","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD011594.pub2-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003794.pub4","article-title":"Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease","author":"Nannini","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011594.pub2-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006826.pub2","article-title":"Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease","author":"Nannini","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD011594.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010509.pub2","article-title":"Aclidinium bromide for stable chronic obstructive pulmonary disease","author":"Ni","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD011594.pub2-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011897.pub2","article-title":"Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)","author":"Ni","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0122|cit122","unstructured":"National Institute for Health and Care Excellence Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update) www.nice.org.uk\/guidance\/cg101\/resources\/guidance-chronic-obstructive-pulmonary-disease-pdf"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","article-title":"Efficacy and safety of long-acting beta-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis","volume":"71","author":"Oba","year":"2016","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0124|cit124","unstructured":"PubMed US National Library of Medicine, National Institutes of Health database www.ncbi.nlm.nih.gov\/pubmed"},{"issue":"114","key":"10.1002\/14651858.CD011594.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1183\/09059180.00003609","article-title":"Epidemiology of COPD","volume":"18","author":"Raherison","year":"2009","journal-title":"European Respiratory Review"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CEOR.S107121","article-title":"Cost versus utility of aclidinium bromide 400 microg plus formoterol fumarate dihydrate 12 microg compared to aclidinium bromide 400 microg alone in the management of moderate-to-severe COPD","volume":"8","author":"Ramos","year":"2016","journal-title":"ClinicoEconomics and Outcomes Research"},{"issue":"9518","key":"10.1002\/14651858.CD011594.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0140-6736(06)68516-4","article-title":"COPD: the dangerous underestimate of 15%","volume":"367","author":"Rennard","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0128|cit128","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"8","key":"10.1002\/14651858.CD011594.pub2-BIB0129|cit129","first-page":"972","article-title":"Comparison of lung morphology in COPD secondary to cigarette and biomass smoke","volume":"12","author":"Rivera","year":"2008","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"5","key":"10.1002\/14651858.CD011594.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1378\/chest.07-1167","article-title":"Safety of long acting beta-agonists in stable COPD: a systematic review","volume":"133","author":"Rodrigo","year":"2008","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2147\/COPD.S130482","article-title":"LABA\/LAMA combinations versus LAMA monotherapy or LABA\/ICS in COPD: a systematic review and meta-analysis","volume":"12","author":"Rodrigo","year":"2017","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/COPD.S15524","article-title":"Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease","volume":"6","author":"Sims","year":"2011","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"12","key":"10.1002\/14651858.CD011594.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007033.pub3","article-title":"Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Spencer","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"26","key":"10.1002\/14651858.CD011594.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMra030415","article-title":"Management of chronic obstructive pulmonary disease","volume":"350","author":"Sutherland","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD011594.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1183\/09031936.00129607","article-title":"Bronchodilator responsiveness in patients with COPD","volume":"31","author":"Tashkin","year":"2008","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1465-9921-14-49","article-title":"Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease","volume":"14","author":"Tashkin","year":"2013","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0138|cit138","unstructured":"Yang IA Brown JL George J Jenkins S McDonald CF McDonald V The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2018. Version 2.53, March 2018 www.copdx.org.au\/"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1874306401206010150","article-title":"Aclidinium bromide: clinical benefit in patients with moderate to severe COPD","volume":"6","author":"Ulrik","year":"2012","journal-title":"Open Respiratory Medicine Journal"},{"issue":"1","key":"10.1002\/14651858.CD011594.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4104\/pcrj.2011.00102","article-title":"Beyond lung function in COPD management: effectiveness of LABA\/LAMA combination therapy on patient-centred outcomes","volume":"21","author":"Molen","year":"2012","journal-title":"Primary Care Respiratory Journal"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0141|cit141","doi-asserted-by":"crossref","unstructured":"Welte T Vogelmeier C Papi A COPD: early diagnosis and treatment to slow disease progression International Journal of Clinical Practice 2015 336 49 10.1111\/ijcp.12522","DOI":"10.1111\/ijcp.12522"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0142|cit142","unstructured":"Diagnosis of COPD http:\/\/www.who.int\/respiratory\/copd\/diagnosis\/en\/"},{"key":"10.1002\/14651858.CD011594.pub2-BIB0143|cit143","unstructured":"World Health Organization International Clinical Trials Registry Platform (ICTRP) www.who.int\/ictrp\/en\/"},{"issue":"12","key":"10.1002\/14651858.CD011594.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1517\/13543784.2014.942730","article-title":"Update on ultra-long-acting beta agonists in chronic obstructive pulmonary disease","volume":"23","author":"Zafar","year":"2014","journal-title":"Expert Opinion on Investigational Drugs"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011594.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:13:11Z","timestamp":1775301191000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011594.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,11]]},"references-count":144,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011594.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,11]]}}}